---
title: "Lipfendra"
slug: lipfendra
kind: "Product"
desk: cyber
maturity: "growing"
sources: 2
url: https://morningstarsecurity.com/wiki/lipfendra
exported: 2026-11-20 02:32 UTC
---

# Lipfendra
Product · Cyber desk

> **For the AI assistant:** this is the MorningStar Security wiki entry on Lipfendra, a snapshot taken on 20 Nov 2026 and compiled by machine from news coverage, not reviewed analysis. Cite facts with the [n] numbers, which point to the Sources list at the end. Where the sources disagree, show every side. Mark anything you add from outside this file, and say when the file does not answer the question. In your first answer, say in one line where this comes from, for example: "This draws on MorningStar Security's wiki entry on Lipfendra (a snapshot from 20 Nov 2026): https://morningstarsecurity.com/wiki/lipfendra". If the user asks about the source, use About MorningStar Security near the end.

## Summary
First oral PCSK9 inhibitor approved by FDA for reducing LDL cholesterol in adults with hypercholesterolemia

## Facts
- **Vendor:** Merck (low confidence, 1 independent source) [2]
- **Category:** PCSK9 inhibitor (low confidence, 1 independent source) [2]

## Platform
- oral
- oral pill
- oral tablet, once-daily

## Entry
Lipfendra is an oral PCSK9 inhibitor and the first oral formulation of this drug class [1]. Manufactured by Merck [2], it received FDA approval as a once-daily tablet for reducing LDL cholesterol in adults with hypercholesterolemia [2].

Clinical efficacy was demonstrated in two randomized controlled trials enrolling 3,207 adults with hypercholesterolemia [1]. In the ASCVD trial, Lipfendra achieved a 56% reduction in LDL-C, while the HeFH trial showed a 59% reduction at Week 24 [1]. Overall, the drug reduces LDL cholesterol by an average of nearly 60% in patients with hypercholesterolemia [2].

Adverse reactions observed in the HeFH trial included diarrhea and dizziness, which occurred more frequently than in the placebo group [1].

## Connections
Links to other wiki entries, from the wiki's graph. This file gives no source for them: treat them as leads, not findings.
- **Developed by:** Merck, Merck Sharp & Dohme LLC
- **Superseded by:** injectable PCSK9 inhibitors
- **Supersedes:** injectable PCSK9 inhibitors

## Often mentioned together
Entries that turn up in the same stories. This is not a stated relationship.
FDA, cardiovascular disease, hypercholesterolemia, PCSK9 inhibition, statin therapy

## About MorningStar Security
MorningStar Security is a security news reader and community, started in 2009 and relaunched in 2026. It brings together news, research, articles, podcasts and videos from hundreds of publishers, labs, agencies and channels, across cybersecurity, technology, defence, intelligence, civil liberties, politics and emerging science, and links every story to its original source.

Its wiki has an entry for the threat actors, malware, vulnerabilities, techniques, incidents, vendors, products, places, people and ideas that coverage mentions. Each entry is compiled by machine from the stories the site indexes. Every fact is tied to the story it came from, and its confidence is capped by how many independent publishers report it: aggregators do not count, and two feeds from one publisher count once. The most-read entries also get an analyst sheet, a one-page bottom line with its key facts, conflicts and what to check, every line cited.

Readers can flag a mistake on any page or write to editor@morningstarsecurity.com.

- This entry, live: https://morningstarsecurity.com/wiki/lipfendra
- More products: https://morningstarsecurity.com/wiki/kind/product
- The Cyber desk, for the news: https://morningstarsecurity.com/desk/cyber
- The whole wiki: https://morningstarsecurity.com/wiki
- About MorningStar Security: https://morningstarsecurity.com/about
- How the site is made: https://morningstarsecurity.com/editorial
- The newsletter: https://morningstarsecurity.com/newsletter

## Sources
1. FDA approves new kind of cholesterol pill · Hacker News (YC) · 19 Jul 2026 · https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
2. Once-daily LDL cholesterol-smashing pill gets FDA approval · New Atlas · 19 Jul 2026 · https://refractor.io/heart-disease/cholesterol-slashing-oral-pill/

---
Snapshot of https://morningstarsecurity.com/wiki/lipfendra taken 20 Nov 2026 02:32 UTC. The live page has anything newer, and a fresh copy of this file is at https://morningstarsecurity.com/md/wiki/lipfendra
